Core Viewpoint - The report from CMB International highlights that after resolving capacity constraints, the sales of Nanfukang have rapidly increased in August, exceeding both the firm's and market expectations for the first eight months of 2025, leading to an upward revision of sales guidance by management, reflecting strong confidence in clinical data and commercialization capabilities [1] Group 1: Company Performance - The company reported a 48% year-on-year revenue growth in the first half of the year, reaching 446 million RMB [1] - Sales of Yijia and Nanfukang grew by 6% and 81% respectively, amounting to 143 million RMB and 303 million RMB [1] - Based on the strong sales performance of Nanfukang, the firm has raised its revenue forecasts for 2026 and 2027 by 16% to 18% [1] Group 2: Market Outlook - CMB International is optimistic about the company's long-term growth driven by the commercialization of its major products and self-research platform [1] - The target price for the company has been raised from 72.5 HKD to 84 HKD, corresponding to a peak revenue multiple of 2.1 times [1] - The firm notes that the second half of this year through 2026 will be rich in catalysts, including the approval of Aiqumou in China, commercialization, and negotiations with medical insurance, as well as business development opportunities for self-research pipelines [1]

Core Viewpoint - CICC's report indicates that Genscript Biotech's performance in the first half of the year met expectations, with a year-on-year revenue growth of 48% to 446 million yuan [1] Revenue Performance - Total revenue reached 446 million yuan, driven by strong terminal demand [1] - The contribution from the product "Nai Fu Kang" was 303 million yuan, reflecting a year-on-year growth of 81% [1] Sales Forecast Adjustment - Due to robust demand, CICC has raised the sales forecast for Nai Fu Kang for the next two years [1] - The profit forecast for 2026 has been revised from 12 million yuan to 119 million yuan [1] Rating and Target Price - CICC maintains a "outperforming the industry" rating for Genscript Biotech [1] - The target price has been increased by 10% to 88 HKD, as the market begins to factor in the company's overseas pipeline expectations into its valuation [1]

Group 1 - The core viewpoint of the report is that due to strong demand for Naisukan, the sales forecast for 2025 and 2026 has been raised, with the 2026 profit forecast adjusted from 0.12 million to 1.19 million [1] - The company reported a revenue of 4.46 billion for 1H25, representing a year-on-year growth of 48%, with Naisukan contributing 3.03 billion, a growth of 81% [2] - The company has set a sales target for Naisukan of 12-14 billion for 2025, which is over 200% growth year-on-year, and 24-26 billion for 2026, approximately 100% growth year-on-year [2] Group 2 - The company is focusing on the progress of EVER001 and mRNA platform for overseas development, with EVER001 being a new generation covalent reversible BTK inhibitor showing positive results in clinical trials [3] - The personalized tumor vaccine EVM16 has completed initial research phases with positive preliminary data, while the universal tumor therapeutic vaccine EVM14 received FDA IND approval in March 2025 [3] - The company's In vivo CAR-T platform has completed several studies in non-human primates, with plans to initiate clinical trials by the end of the year [3]

Group 1 - The core viewpoint is that due to strong demand for Nanfukang, the sales forecast for 2025 and 2026 has been raised, with a significant adjustment in the 2026 profit forecast from 0.12 million to 1.19 million [1] - The company reported a revenue of 4.46 billion for 1H25, representing a year-on-year growth of 48%, with Nanfukang contributing 3.03 billion, a growth of 81% [2] - Nanfukang's sales target for 2025 is set at 12-14 billion, indicating a year-on-year growth of over 200%, while the target for 2026 is 24-26 billion, reflecting a growth of approximately 100% [2] Group 2 - The company is focusing on the progress of EVER001 and mRNA platform for overseas expansion, with positive results from ongoing clinical trials for kidney disease treatments [3] - The personalized tumor vaccine EVM16 has completed initial research phases with positive preliminary data, while the universal tumor therapeutic vaccine EVM14 received FDA IND approval in March 2025 [3] - The company plans to initiate clinical trials for its In vivo CAR-T platform by the end of the year after completing several studies on non-human primates [3]

Core Viewpoint - The report from CMB International indicates that Genting New Year achieved a 48% year-on-year revenue growth to 446 million yuan in the first half of the year, driven by significant sales increases in its key products [1] Group 1: Financial Performance - Genting New Year’s revenue reached 446 million yuan, marking a 48% increase year-on-year [1] - Sales of Yijia and Naifukang grew by 6% and 81% respectively, amounting to 143 million yuan and 303 million yuan [1] - Following the resolution of capacity constraints, Naifukang saw rapid sales growth in August, exceeding both the bank's and market expectations for the first eight months of 2025 [1] Group 2: Management Outlook - The management has raised its sales guidance, reflecting strong confidence in the clinical data and commercialization capabilities of its products [1] - The company is expected to benefit from a dual-driven growth model through the commercialization of its major products and self-research platform [1] Group 3: Future Catalysts and Valuation - The bank has raised its target price from 72.5 HKD to 84 HKD, corresponding to a 2.1 times peak revenue sales multiple, maintaining a "Buy" rating [1] - The second half of this year through 2026 is anticipated to have rich catalysts, including the approval of Aiqumou in China, commercialization, and negotiations with health insurance, as well as business development opportunities for self-research pipelines [1] - Based on the strong sales performance of Naifukang, the bank has increased its revenue forecasts for 2026 to 2027 by 16% to 18%, along with a more optimistic outlook on operating expense ratios [1]

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expectation of total returns exceeding the relevant industry over the next 12 months [3][12]. Core Insights - The company has experienced rapid sales growth following the resolution of capacity constraints, with sales for the first eight months of 2025 exceeding both the report's and market expectations. The management has raised sales guidance, reflecting strong confidence in clinical data and commercialization capabilities [2][7]. - The target price has been raised to HKD 84.00, representing a potential upside of 32.2% from the current price of HKD 63.55 [1][12]. Financial Performance Summary - Revenue for 2025 is projected at RMB 1,611 million, with a significant increase to RMB 2,951 million in 2026 and RMB 4,408 million in 2027, reflecting a growth trajectory [6][13]. - The company reported a net loss of RMB 160 million for 2025, with expectations of turning profitable by 2026 with a net profit of RMB 325 million [6][13]. - The gross profit margin is expected to stabilize around 70% in 2025, improving to 73% in 2026 and 74.5% in 2027 [6][13]. Sales and Market Dynamics - The company’s flagship product, Nanfukang, has seen sales growth of 81% year-on-year, with total sales expected to reach RMB 12-14 billion for the year, and potentially doubling to RMB 24-26 billion in 2026 [7][8]. - The company is also advancing its pipeline with promising clinical data, particularly for its third commercialized product, which is anticipated to achieve peak sales of RMB 5 billion [7][8]. Valuation and Future Outlook - The report utilizes a DCF model to arrive at a target price of HKD 84.00, based on optimistic revenue forecasts and improved operating expense ratios [8][12]. - The company is expected to achieve operational breakeven in the second half of 2025, earlier than previously anticipated [7][8].

交银国际研究 每日晨报 2025 年 9 月 1 日 今日焦点 每月金股 九月研选-宏观环境趋稳+流动性宽松，港股有望 延续向好态势 交银国际研究团队 宏观不确定性持续消退，全球风险偏好明显回升。8 月以来海外宏观环境的 不确定性延续降温态势，美国与主要经济体就贸易框架达成初步共识，同时 宣布将对华关税措施延迟 90 天实施并继续推进双边谈判。与此同时，欧洲 地缘冲突相关谈判有所转机，整体局势边际缓解。 "反内卷"政策效应持续释放，流动性波动对交投活跃度形成扰动。"反内卷" 政策持续推进，相关预期继续推动传统周期行业及部分新兴产业龙头企业的 估值修复进程。 海内外流动性宽松周期下，港股有望延续向好势头。当前我国流动性延续宽 松，A 股市场情绪活跃，亦有望提振港股交易氛围。南向资金对港股科技等 板块的配置需求保持旺盛，资金净流入态势有望延续。海外方面，美联储主 席鲍威尔杰克逊霍尔释放 9 月降息大门敞开的信号，港股有望受益于外资流 入的增加。 九月研选 | 全球主要指数 | | | | | --- | --- | --- | --- | | | 收盘价 | 升跌% | 年初至今 升跌% | | 恒指 | 25, ...

Summary of Key Points from the Conference Call Company Overview - **Company**: 云顶新耀 (Genting New Horizon) - **Industry**: Biotechnology and Pharmaceuticals Financial Performance - **2025 Revenue Forecast**: Expected total revenue of 16-18 billion RMB, with耐赋康 (Nai Fu Kang) sales projected at 12-14 billion RMB, potentially becoming the first non-oncology drug to exceed 1 billion RMB in sales in its first year post-medical insurance inclusion [1][4] - **2025 H1 Revenue**: Achieved 4.46 billion RMB, a 48% year-on-year increase [6] - **Cash Position**: Cash balance of 1.6 billion RMB as of June 30, 2025, following a successful 1.6 billion HKD equity financing [6] Product Performance - **耐赋康 (Nai Fu Kang)**: - Strong market performance with 8.2 billion RMB in revenue from January to August 2025, including 5.2 billion RMB in August alone [1][8] - Expected sales of 12-14 billion RMB in 2025 and 24-26 billion RMB in 2026, driven by medical insurance coverage and expanding patient demand [10] - Currently included in the national medical insurance directory across 29 provinces [2] - **艾曲莫德 (Ai Qu Mo De)**: - Considered a second major product targeting ulcerative colitis, with peak sales expected to reach 5 billion RMB [15] - Anticipated approval in H1 2026, showcasing strong mucosal healing capabilities [15][18] Research and Development - **MRNA Platforms**: - Progress in MRNA self-generating CAR-T platform, with clinical development expected to start by the end of 2025 [5] - Multiple products in the MRNA tumor vaccine pipeline, including EVM16, TAAEV M14 (approved by the US IND), and EVN15 [5][24] - **Clinical Trials**: - 西布替尼 (Xibu Tini) shows promising results in primary membranous nephropathy, with plans for registration clinical trials in 2026 [20][22] - gdig test reagent for IgA nephropathy is under development, expected to enhance patient compliance and diagnosis accuracy [13] Market Strategy - **Commercialization Model**: - Aiming to expand hospital coverage to 1,000 hospitals, targeting 80% of market potential [11] - Plans for international market entry, including regions like South Korea and Taiwan [11] - **Insurance Negotiations**: - Preparing for favorable conditions in upcoming medical insurance negotiations to support product launches [3][12] Competitive Landscape - **Market Position**: -耐赋康 is the first and only fully approved IgA nephropathy treatment included in the national medical insurance directory, with a two-year exclusivity period [10][50] -艾曲莫德 is positioned to address unmet needs in ulcerative colitis, with significant market potential due to the high prevalence of the disease [15][40] Future Outlook - **Sales Projections**: - Confident in achieving 12-14 billion RMB in sales for 2025, with expectations to double in 2026 [12][34] - **R&D Investment**: - Continued investment in high-barrier platforms, with a focus on autoimmune diseases and CRMI platforms [44] - **Strategic Partnerships**: - Actively seeking collaborations to enhance product development and market reach, particularly in the MRNA and CAR-T sectors [46][48] Conclusion - **Growth Strategy**: - The company is positioned for significant growth through its innovative product pipeline, strong financial health, and strategic market expansion efforts, aiming to become a leading player in the global biopharmaceutical industry [51]

Group 1 - The core viewpoint of the articles highlights the strong financial performance and growth prospects of CloudTop New Medicine, with significant revenue increases and a solid cash reserve [1][2] Group 2 - For the first half of 2025, CloudTop New Medicine reported a revenue of 446 million yuan, representing a 48% year-on-year increase, with a gross margin of 76.4% [1] - The company narrowed its non-IFRS losses by 31% compared to the previous year, indicating improved operational efficiency [1] - As of mid-2025, the cash balance reached 1.6 billion yuan, supplemented by recent equity financing of 1.553 billion HKD, bringing total cash reserves to over 2.5 billion yuan [1] Group 3 - In the nephrology treatment sector, the main product, Nefukang, saw a sales revenue of 303 million yuan in the first half of 2025, an 81% increase year-on-year, with cumulative sales reaching 825 million yuan from January to August [1] - The management expects Nefukang's annual sales to exceed 1.2 billion to 1.4 billion yuan, with projections for 2026 indicating potential sales growth to 2.4 billion to 2.6 billion yuan [1] Group 4 - The antibiotic product, Yijia, also showed stable growth, with revenue of 143 million yuan in the first half of 2025, a 6% increase year-on-year, and a 37% increase in direct sales to core hospitals [1] Group 5 - The CEO of CloudTop New Medicine emphasized the success of the "dual-drive" strategy, focusing on high-potential markets and self-developed platforms, which has led to breakthroughs in commercialization and research [2] - The company is confident in achieving an annual sales target of 1.6 billion to 1.8 billion yuan and expects to turn positive in operating cash flow by the fourth quarter [2]

Group 1 - The company is confident in achieving its annual sales target of 1.6 billion to 1.8 billion yuan, aiming for operational profitability by the second half of 2025 [1][2] - The core product, Nefikastat, has shown exceptional performance with sales revenue of 303 million yuan in the first half of the year, representing an 81% year-on-year increase [1] - As of August, the sales team in the nephrology sector has expanded to 190 members, covering 1,000 target hospitals, with approximately 30,000 new patients expected by the first half of 2025 [1] Group 2 - The company reported a revenue of 446 million yuan for the first half of 2025, a 48% year-on-year increase, with a gross margin of 76.4% [4] - The non-IFRS loss has narrowed by 31% year-on-year, indicating a continued approach towards profitability [4] - The cash balance at the end of the first half reached 1.6 billion yuan, supplemented by recent fundraising of 1.553 billion HKD, bringing total cash reserves to over 2.5 billion yuan [4] Group 3 - The company is focusing on its self-developed core pipeline and accelerating the clinical development and internationalization of global rights products [1] - The product pipeline includes personalized tumor therapeutic vaccines, mRNA tumor therapeutic vaccines, and self-generated CAR-T projects [2] - The CEO emphasized the dual-driven strategy to establish a commercial platform for high-potential markets and to advance the self-generated CAR-T and mRNA vaccine platforms [2]